The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Abstract
Background The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of first-line alemtuzumab compared with interferon beta 1a in a phase 3 trial.Methods In our 2 year, rater-masked, randomised controlled phase 3 trial, we enrolled adults aged 18-50 years with previously untreated relapsing-remitting multiple sclerosis. Eligible participants were randomly allocated in a 2:1 ratio by an interactive voice response system, stratified by site, to receive intravenous alemtuzumab 12 mg per day or subcutaneous interferon beta 1a 44 μg. Interferon beta 1a was given three-times per week and alemtuzumab was given once per day for 5 days at baseline and once per day for 3 days at 12 months. Coprimary endpoints were relapse rate and time to 6 month sustained accumulation of disability in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT00530348.Findings 187 (96%) of 195 patients randomly allocated interferon beta 1a and 376 (97%) of 386 patients randomly allocated alemtuzumab were included in the primary analyses. 75 (40%) patients in the interferon beta 1a group relapsed (122 events) compared with 82 (22%) patients in the alemtuzumab group (119 events; rate ratio 0·45 [95% CI 0·32-0·63]; p<0.0001), corresponding to a 54·9% improvement with alemtuzumab. Based on Kaplan-Meier estimates, 59% of patients in the interferon beta 1a group were relapse-free at 2 years compared with 78% of patients in the alemtuzumab group (p<0·0001). 20 (11%) of patients in the interferon beta 1a group had sustained accumulation of disability compared with 30 (8%) in the alemtuzumab group (hazard ratio 0·70 [95% CI 0·40-1·23]; p=0·22). 338 (90%) of patients in the alemtuzumab group had infusion-associated reactions; 12 (3%) of which were regarded as serious. Infections, predominantly of mild or moderate severity, occurred in 253 (67%) patients treated with alemtuzumab versus 85 (45%) patients treated with interferon beta 1a. 62 (16%) patients treated with alemtuzumab had herpes infections (predominantly cutaneous) compared with three (2%) patients treated with interferon beta 1a. By 24 months, 68 (18%) patients in the alemtuzumab group had thyroid-associated adverse events compared with 12 (6%) in the interferon beta 1a group, and three (1%) had immune thrombocytopenia compared with none in the interferon beta 1a group. Two patients in the alemtuzumab group developed thyroid papillary carcinoma.Interpretation Alemtuzumab's consistent safety profile and benefit in terms of reductions of relapse support its use for patients with previously untreated relapsing-remitting multiple sclerosis; however, benefit in terms of disability endpoints noted in previous trials was not observed here.Funding Genzyme (Sanofi) and Bayer Schering Pharma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the phase III clinical trials comparing alemtuzumab with interferon β-1a in highly active MS, no overall increase in malignancy was observed;”
From 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy (2019) · cites this paper as [60]
In the citing paper
“however, papillary thyroid cancer was discovered in 0.4% of alemtuzumab-treated patients [59, 60].”
From 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy (2019) · cites this paper as [60]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017
Self-citationThe Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Multiple Comparison Procedures
Hochberg, Y., & Tamhane, A. C. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316672 · Cited by 2,389
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comı, G., Hartung, H., Khatri, B. O., Montalbán, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,220
Self-citationMultiple Comparison Procedures
Hahs-Vaughn, D., & Lomax, R. (2013) · Routledge eBooks · doi:10.4324/9780203137819-17 · Cited by 2,132
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E. W., LUBLIN, F. D., Weinstock‐Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,342
Self-citationDiagnostic criteria for multiple sclerosis
Poser, C. M., & Brinar, V. V. (2001) · Clinical Neurology and Neurosurgery · doi:10.1016/s0303-8467(00)00125-6 · Cited by 1,282
Self-citationColes, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
Self-citationDevelopment of a multiple sclerosis functional composite as a clinical trial outcome measure
Cutter, G. (1999) · Brain · doi:10.1093/brain/122.5.871 · Cited by 1,191
Cited by
Sorted by citations
Items 301–400 of 1,000
Fingolimod for the treatment of relapsing multiple sclerosis
Jeffery, D., Markowitz, C., Reder, A. T., Weinstock‐Guttman, B., & Tobias, K. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.193 · Cited by 37
Fahrbach, K. R., Huelin, R., Martin, A. L., Kim, E., Dastani, H. B., Rao, S. M., & Malhotra, M. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-180 · Cited by 36
Graves’ disease after treatment with Alemtuzumab for multiple sclerosis
Tsourdi, E. A., Grüber, M., Rauner, M., Blankenburg, J., Ziemssen, T., & Hofbauer, L. C. (2014) · HORMONES · doi:10.14310/horm.2002.1501 · Cited by 36
Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.
Zadeh, A. R., Ghadimi, K., Ataei, A., Askari, M., Sheikhinia, N., Tavoosi, N., & Falahatian, M. (2019) · PubMed · Cited by 36
Multiple Sclerosis Pathogenesis and Updates in Targeted Therapeutic Approaches
Vasileiou, E. S., & Fitzgerald, K. C. (2023) · Current Allergy and Asthma Reports · doi:10.1007/s11882-023-01102-0 · Cited by 41
Yamout, B., Alroughani, R., Aljumah, M., Gouider, R., Dahdaleh, M., Inshasi, J. S. S., Hashem, S., Alsharoqi, I., Sahraian, M. A., Khoury, S. J., et al. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1047750 · Cited by 37
Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?
Havla, J. B., Kleiter, I., & Kümpfel, T. (2013) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s41552 · Cited by 34
Update on treatments in multiple sclerosis
Michel, L., Larochelle, C., & Prat, A. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.02.008 · Cited by 38
Alemtuzumab for the treatment of multiple sclerosis
Evan, J. R., Bozkurt, S. B., Thomas, N. C., & Bagnato, F. R. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1425388 · Cited by 34
Huhn, K., Bayas, A., Doerck, S., Frank, B., Gerbershagen, K., Hellwig, K., Kallmann, B. A., Kleinschnitz, C., Kleiter, I., Lee, D.-H., et al. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8871-2 · Cited by 35
Treating relapsing–remitting multiple sclerosis: therapy effects on brain atrophy
Vidal‐Jordana, Á., Sastre‐Garriga, J., Rovira, À., & Montalbán, X. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7798-0 · Cited by 35
Weissert, R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00336 · Cited by 37
Alemtuzumab as Treatment for Multiple SclerosisPreprint
Katsavos, S., & Coles, A. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a032029 · Cited by 35
Self-citationMuller, I., Willis, M., Healy, S., Nasser, T., Loveless, S., Butterworth, S., Zhang, L., Draman, M. S., Taylor, P. N., Robertson, N., et al. (2018) · Thyroid · doi:10.1089/thy.2018.0232 · Cited by 34
Whole-brain atrophy: ready for implementation into clinical decision-making in multiple sclerosis?
Azevedo, C., & Pelletier, D. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000322 · Cited by 32
Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab
Barton, J., Hardy, T. A., Riminton, S., Reddel, S., Barnett, Y., Coles, A. J., & Barnett, M. H. (2017) · Neurology · doi:10.1212/wnl.0000000000003694 · Cited by 34
Self-citationBaker, D., Giovannoni, G., & Schmierer, K. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.09.028 · Cited by 34
Self-citationProtein‐Engineered Biomaterials for Cancer Theranostics
Liu, X., Wang, C., & Liu, Z. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800913 · Cited by 34
Phelps, R. G., Winston, J. A., Wynn, D. R., Habek, M., Hartung, H., Havrdová, E., Markowitz, G. S., Margolin, D. H., Rodriguez, C. E., Baker, D. P., et al. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519841829 · Cited by 34
Self-citationA narrative review of psoriasis and multiple sclerosis: links and risks
Silfvast‐Kaiser, A., Homan, K. B., & Mansouri, B. (2019) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s186637 · Cited by 35
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
Möhn, N., Pfeuffer, S., Ruck, T., Groß, C. C., Skripuletz, T., Klotz, L., Wiendl, H., Stangel, M., & Meuth, S. G. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000654 · Cited by 34
Alsharoqi, I. A., Aljumah, M., Bohlega, S., Boz, C., Daif, A., El-Koussa, S., Inshasi, J. S. S., Kürtüncü, M., Müller, T., Retief, C., et al. (2020) · Neurology and Therapy · doi:10.1007/s40120-020-00187-3 · Cited by 37
The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
Rolla, S., Maglione, A., Mercanti, S. F. D., & Clerico, M. (2020) · Cells · doi:10.3390/cells9061396 · Cited by 36
Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
Wiendl, H., & Meuth, S. G. (2015) · Drugs · doi:10.1007/s40265-015-0411-0 · Cited by 34
Autoimmune Thyroid Disease in the Use of Alemtuzumab for Multiple Sclerosis: A Review
Aranha, A. A., Amer, S., Reda, E. S., Broadley, S., & Davoren, P. M. (2013) · Endocrine Practice · doi:10.4158/ep13020.ra · Cited by 35
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
Arnold, D. L., Fisher, E., Brinar, V. V., Cohen, J. A., Coles, A. J., Giovannoni, G., Hartung, H.-P., Havrdová, E., Selmaj, K. W., Stojanovic, M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003169 · Cited by 34
Self-citationThe Spectrum of Inflammatory Acquired Demyelinating Syndromes in Children
Neuteboom, R. F., Wilbur, C., van Pelt, D., Rodriguez, M., & Yeh, E. A. (2017) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2017.08.007 · Cited by 37
Emerging injectable therapies for multiple sclerosis
Oh, J., & Calabresi, P. A. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70192-3 · Cited by 33
Hussain, R. Z., Hayardeny, L., Cravens, P. D., Yarovinsky, F., Eagar, T. N., Arellano, B., Deason, K. L., Castro-Rojas, C. M., & Stüve, O. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.08.622 · Cited by 36
González, R. V. A., Kita, M., Crayton, H. J., Havrdová, E., Margolin, D. H., Lake, S. L., Giovannoni, G., & on behalf of the CARE-MS I and II Investigators (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516677589 · Cited by 33
Self-citationActivation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis
Wehrum, T., Beume, L.-A., Stich, O., Mader, I., Mäurer, M., Czapliński, A., Weiller, C., & Rauer, S. (2018) · Neurology · doi:10.1212/wnl.0000000000004950 · Cited by 33
Baker, D., Ali, L., Saxena, G., Pryce, G., Jones, M., Schmierer, K., Giovannoni, G., Gnanapavan, S., Munger, K. C., Samkoff, L., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00124 · Cited by 34
Self-citationThe Emerging Jamboree of Transformative Therapies for Autoimmune Diseases
Carballido, J. M., Regairaz, C., Rauld, C., Raad, L., Picard, D., & Kammuller, M. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00472 · Cited by 35
Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis
Moiola, L., Rommer, P. S., & Zettl, U. K. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000824 · Cited by 34
Update on immunopathogenesis and immunotherapy in multiple sclerosis
Hemmer, B., & Selter (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s31813 · Cited by 33
Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations
Salter, A. R., Lancia, S., Kowalec, K., Fitzgerald, K. C., & Marrie, R. A. (2024) · Neurology · doi:10.1212/wnl.0000000000209135 · Cited by 35
Cost-utility of First-line Disease-modifying Treatments for Relapsing–Remitting Multiple Sclerosis
Soini, E. J., Joutseno, J., & Sumelahti, M. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.028 · Cited by 32
Pfeuffer, S., Ruck, T., Pul, R., Rolfes, L., Korsukewitz, C., Pawlitzki, M., Wildemann, B., Klotz, L., Kleinschnitz, C., Scalfari, A., et al. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-325304 · Cited by 32
Treatment of Multiple Sclerosis
Cross, A., & Riley, C. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001170 · Cited by 37
Chirikov, V., Ma, I., Joshi, N., Patel, D. A., Smith, A. F., Giambrone, C., Cornelio, N., & Hashemi, L. (2018) · Value in Health · doi:10.1016/j.jval.2018.08.011 · Cited by 32
Silfverberg, T., Zjukovskaja, C., Ljungman, P. T., Nahimi, A., Ahlstrand, E., Dreimane, A., Einarsdottir, S., Fagius, J., Iacobaeus, E., Hägglund, H., et al. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-331864 · Cited by 32
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
Lugaresi, A., Travaglini, Pietrolongo, E., Pucci, E., ONOFRJ, M. C., & di Ioia, M. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s45144 · Cited by 31
Hands on Alemtuzumab-experience from clinical practice: whom and how to treat
Hassoun, L., Eisele, J., Thomas, K., & Ziemssen, T. (2016) · Multiple Sclerosis and Demyelinating Disorders · doi:10.1186/s40893-016-0011-1 · Cited by 31
Xu, D. Q., Smolin, N., Shaw, R., Battey, S. R., Tao, A., Huang, Y., Rahman, S. E., & Caylor, M. L. (2018) · RSC Advances · doi:10.1039/c7ra12480e · Cited by 31
A case for gender-based approach to multiple sclerosis therapeutics
Houtchens, M. K., & Bove, R. M. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.07.001 · Cited by 33
Alcalá, C., Gascón, F., Miralles, F. C. P., Domínguez, J. A., Gil‐Perotín, S., & Casanova, B. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09195-2 · Cited by 31
Gopaluni, S., Smith, R., Donna, G., Cahill, H., Broadhurst, E., Wallin, E. F., McClure, M., Chaudhry, A., & Jayne, D. R. W. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02761-6 · Cited by 31
Baker, D., MacDougall, A. M., Kang, A. S., Schmierer, K., Giovannoni, G., & Dobson, R. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103448 · Cited by 31
Self-citationPersonalized Use of Disease-Modifying Therapies in Multiple Sclerosis
Lee, C., & Chan, K. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16010120 · Cited by 32
Edan, G., & Page, E. L. (2023) · Drugs · doi:10.1007/s40265-023-01942-0 · Cited by 36
Neurons and T cells: Understanding this interaction for inflammatory neurological diseases
Yshii, L., Gebauer, C., Bernard‐Valnet, R., & Liblau, R. (2015) · European Journal of Immunology · doi:10.1002/eji.201545759 · Cited by 30
Uher, T., Horáková, D., Kalinčík, T., Bergsland, N., Týblová, M., Ramasamy, D. P., Seidl, Z., Vaněčková, M., Krásenský, J., Havrdová, E., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12716 · Cited by 30
Zimmermann, J., Buhl, T., & Müller, M. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00569 · Cited by 30
Keratinocyte growth factor impairs human thymic recovery from lymphopenia
Coles, A. J., Azzopardi, L., Kousin‐Ezewu, O., Mullay, H. K., Thompson, S. A. J., Jarvis, L. B., Davies, J. L., Howlett, S., Rainbow, D. B., Babar, J. L., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125377 · Cited by 30
Self-citationOne, No One, and One Hundred Thousand: T Regulatory Cells' Multiple Identities in Neuroimmunity
Sambucci, M., Gargano, F., Guerrera, G., Battistini, L., & Borsellino, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02947 · Cited by 31
Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab
Matías‐Guiu, J., Montero‐Escribano, P., Pytel, V., Porta-Etessam, J., & Matias-Guiu, J. A. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102297 · Cited by 30
A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis
Bose, G., Rush, C., Atkins, H. L., & Freedman, M. S. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102945 · Cited by 32
Dimitriou, N. G., Meuth, S. G., Martínez‐Lapiscina, E. H., Albrecht, P., & Menge, T. (2023) · CNS Drugs · doi:10.1007/s40263-022-00977-3 · Cited by 31
Alemtuzumab: evidence for its potential in relapsing–remitting multiple sclerosis
Brown, J. W. L., & Coles, A. J. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s32687 · Cited by 30
Self-citationDisease activity return after natalizumab cessation in multiple sclerosis
Rasenack, M., & Derfuss, T. J. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1168295 · Cited by 29
NEDA treatment target? No evident disease activity as an actionable outcome in practice
Parks, N. E., Flanagan, E. P., Lucchinetti, C. F., & Wingerchuk, D. M. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.10.015 · Cited by 30
Members of Danish Multiple Sclerosis Group, Chalmer, T. A., Kalinčík, T., Laursen, B., Sørensen, P. S., & Magyari, M. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9126-y · Cited by 29
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
Ng, H. S., Zhu, F., Kingwell, E., Yao, S., Ekuma, O., Evans, C. D., Fisk, J. D., Marrie, R. A., Zhao, Y., & Tremlett, H. L. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200005 · Cited by 29
van Nederpelt, D. R., Amiri, H., Brouwer, I., Noteboom, S., Mokkink, L. B., Barkhof, F., Vrenken, H., & Kuijer, J. P. A. (2023) · Neuroradiology · doi:10.1007/s00234-023-03189-8 · Cited by 30
Drug therapy for multiple sclerosis
Tavazzi, E., Rovaris, M., & Mantia, L. L. (2014) · Canadian Medical Association Journal · doi:10.1503/cmaj.130727 · Cited by 29
McGinley, M., & Rossman, I. T. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0568-1 · Cited by 29
Estriol‐mediated neuroprotection in multiple sclerosis localized by voxel‐based morphometry
MacKenzie-Graham, A., Brook, J., Kurth, F., Itoh, Y., Meyer, C., Montag, M. J., Wang, H.-J., Elashoff, R., & Voskuhl, R. (2018) · Brain and Behavior · doi:10.1002/brb3.1086 · Cited by 29
Ocrelizumab for the treatment of multiple sclerosis
Bigaut, K., Seze, J. D., & Collongues, N. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1561284 · Cited by 29
Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis
Macaron, G., Feng, J. J., Moodley, M., & Rensel, M. R. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0592-z · Cited by 29
di Ioia, M., Stefano, V. D., Farina, D., di Tommaso, V., Travaglini, D., Pietrolongo, E., Sensi, S. L., ONOFRJ, M. C., & Luca, G. D. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.101504 · Cited by 29
Zecca, C., Caporro, M., Disanto, G., & Gobbi, C. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s68698 · Cited by 30
Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab
Gaitán, M. I., Ysrraelit, M. C., & Correale, J. D. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.1456 · Cited by 28
Rocca, M. A., Preziosa, P., & Filippi, M. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1555038 · Cited by 28
An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion
Alroughani, R., Inshasi, J. S. S., Deleu, D., Al-Hashel, J. Y., Shakra, M., Elalamy, O. R., Shatila, A. O., Al-Asmi, A. R., Sharoqi, I. A., Canibaño, B., et al. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-0129-0 · Cited by 29
Quirant‐Sánchez, B., Mansilla, M. J., Navarro‐Barriuso, J., Presas‐Rodríguez, S., Teniente‐Serra, A., Fondelli, F., Ramo-Tello, C. M., & Martínez-Cáceres, E. M. (2021) · Biomedicines · doi:10.3390/biomedicines9121758 · Cited by 30
Next-generation antibody-based therapies in neurology
Ruck, T., Nimmerjahn, F., Wiendl, H., & Lünemann, J. D. (2021) · Brain · doi:10.1093/brain/awab465 · Cited by 29
Turner, M. J., Pang, P. T., Chrétien, N., Havari, E., LaMorte, M. J., Oliver, J., Pande, N., Masterjohn, E., Carter, K., Reczek, D., et al. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.05.018 · Cited by 28
Schaeffer, J., Cossetti, C., Mallucci, G., & Pluchino, S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398270-4.00030-6 · Cited by 28
Monoclonal Antibodies for Multiple Sclerosis: An Update
Graf, J., Aktaş, O., Rejdak, K., & Hartung, H. (2019) · BioDrugs · doi:10.1007/s40259-018-0327-9 · Cited by 28
Self-citationPresent and Emerging Therapies for Multiple Sclerosis
Freedman, M. S. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000433288.30715.e3 · Cited by 27
Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
Tur, C., Tintoré, M., Vidal‐Jordana, Á., Bichuetti, D. B., González, P., Arévalo, M. J., Arrambide, G., Anglada, E., Galán, I., Castilló, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082796 · Cited by 27
Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs
Milo, R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1002769 · Cited by 27
Havrdová, E., Cohen, J. A., Horáková, D., Kovářová, I., & Meluzínová, E. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s143509 · Cited by 28
Self-citationAlemtuzumab depletion failure can occur in multiple sclerosis
Dubuisson, N., Baker, D., Kang, A. S., Pryce, G., Marta, M., Visser, L. H., Hofmann, W. E., Gnanapavan, S., Giovannoni, G., & Schmierer, K. (2017) · Immunology · doi:10.1111/imm.12879 · Cited by 27
Self-citationPharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview
Angelis, F. D., Plantone, D., & Chataway, J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0538-0 · Cited by 29
Bose, G., & Freedman, M. S. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458519887324 · Cited by 29
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
Sellner, J., & Rommer, P. S. (2021) · Vaccines · doi:10.3390/vaccines9020099 · Cited by 28
Coles, A. J., Jones, J., Vermersch, P., Traboulsee, A. L., Bass, A. D.-D., Boster, A. L., Chan, A., Comı, G., Fernández, Ó., Giovannoni, G., et al. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211061335 · Cited by 27
Self-citationBrain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact
Rojas, J. I., Patrucco, L., Míguez, J., & Cristiano, E. (2016) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20160015 · Cited by 32
Teriflunomide in Multiple Sclerosis: an Update
Miller, A. (2016) · Neurodegenerative Disease Management · doi:10.2217/nmt-2016-0029 · Cited by 27
Efficiency of antibody therapy in demyelinating diseases
Akaishi, T., & Nakashima, I. (2017) · International Immunology · doi:10.1093/intimm/dxx037 · Cited by 27
Coles, A. J., Achiron, A., Traboulsee, A. L., Singer, B. A., Pozzilli, C., Oreja‐Guevara, C., Giovannoni, G., Comı, G., Freedman, M. S., Ziemssen, T., et al. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231194823 · Cited by 26
Self-citationManaging multiple sclerosis in individuals aged 55 and above: a comprehensive review
Fernández, Ó., Sørensen, P. S., Comı, G., Vermersch, P., Hartung, H., Leocani, L., Berger, T., Wijmeersch, B. V., & Oreja‐Guevara, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1379538 · Cited by 30
Self-citationAlemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management
Mahzari, M., Arnaout, A., & Freedman, M. S. (2015) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2015.48 · Cited by 26
Ziemssen, T., Engelmann, U., Jahn, S., Leptich, A., Kern, R., Hassoun, L., & Thomas, K. (2016) · BMC Neurology · doi:10.1186/s12883-016-0629-9 · Cited by 26
Brownlee, W. J., & Chataway, J. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517693440 · Cited by 26
Comparing the efficacy of disease-modifying therapies in multiple sclerosis
Mitsikostas, D. D., & Goodin, D. S. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.08.003 · Cited by 26
Long-term drug treatment in multiple sclerosis: safety success and concerns
Jakimovski, D., Vaughn, C. B., Eckert, S. P., Zivadinov, R., & Weinstock‐Guttman, B. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1805430 · Cited by 25
Costimulation Blockade in Vascularized Composite Allotransplantation
Giannis, D., Moris, D., & Cendales, L. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.544186 · Cited by 26
Jalusic, K. O., Ellenberger, D., Rommer, P. S., Stahmann, A., Zettl, U. K., & Berger, K. (2021) · Multiple Sclerosis Journal · doi:10.1177/1352458520985118 · Cited by 26
Metadata
- Authors
- Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., Brinar, V. V., Giovannoni, G., Stojanovic, M., Ertik, B. I., Lake, S. L., Margolin, D. H., Panzara, M. A., & Compston, D. A. S.
- Affiliations
- Cleveland Clinic (US)
- University of Cambridge (GB)
- Montreal Neurological Institute and Hospital (CA)
- Lyon 1 Université (FR)
- Central Texas Neurology Consultants (US)
- Heinrich Heine University Düsseldorf (DE)
- Medical University of Lodz (PL)
- Brigham and Women's Hospital (US)
- University Hospital Centre Zagreb (HR)
- Queen Mary University of London (GB)
- Clinical Centre of Kragujevac (RS)
- Corresponding author
- Cohen, Jeffrey A
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 380
- Issue
- 9856
- Pages
- 1819-1828
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2148766438
- Cited by
- 1,205
- References
- 39
- Citations by year
- 2026: 25 · 2025: 52 · 2024: 66 · 2023: 71 · 2022: 70 · 2021: 77 · 2020: 109 · 2019: 112 · 2018: 108 · 2017: 120 · 2016: 112 · 2015: 104 · 2014: 85 · 2013: 83 · 2012: 6
- FWCI
- 64.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0508-10335)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- alemtuzumab, interferon beta-1a, relapsing-remitting multiple sclerosis, first-line therapy, anti-CD52 monoclonal antibody, relapse rate, disability progression, disease-modifying therapy, treatment safety, treatment-naive patients, relapse-free survival, time to treatment discontinuation, adverse events, immunosuppression
- MeSH terms
- Interferon beta-1a, Alemtuzumab, Adjuvants, Immunologic, Administration, Cutaneous, Adolescent, Adult, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Recurrence, Treatment Outcome, Interferon-beta, Disease-Free Survival, Multiple Sclerosis, Relapsing-Remitting, Kaplan-Meier Estimate, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
